Research Interests
Clinical trials, clinical research innovation, clinical pharmacology and coordinating center work.
Selected Grants
iPediHeart: Interdisciplinary Research Training Program for Pediatric Heart Disease
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2025 - 20302/3 CTSA K12 Program at Duke University
ResearchMentor · Awarded by National Institutes of Health · 2025 - 2030Unified Program for Therapeutics in Children
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030Short-course ampicillin in preterm neonates to promote antimicrobial stewardship
ResearchCo-Mentor · Awarded by National Institutes of Health · 2025 - 2029Direct-to-family pharmacokinetics intervention for hydroxychloroquine non-adherence in adolescents with systemic lupus erythematosus
ResearchAdvisor · Awarded by National Institute of Arthritis and Musculoskeletal and Skin Diseases · 2024 - 2029Stimulating Access to Research in Residency (StARR) - NIAID
Inst. Training Prgm or CMEPreceptor · Awarded by National Institute of Allergy and Infectious Diseases · 2018 - 2029Stimulating Access to Research in Residency (StARR) - NHLBI
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 2018 - 2028NIH HEAL Initiative Research-Dissemination and Engagement Center (R-DEC). CORE 3: Project Management
ResearchCo Investigator · Awarded by National Institutes of Health · 2022 - 2027Application of Physiologically-Based Pharmacokinetic Modeling to Characterize Drug-Drug Interactions in Infants
ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2027Duke Center for Advancement of Child Health (CAtCH).
Inst. Training Prgm or CMEMentor · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2021 - 2027Real World Data to Support Pediatric Drug Labeling
ResearchCo Investigator · Awarded by Burroughs Wellcome Fund · 2019 - 2026UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2016 - 2026Pediatric Trials Network_ Task Order 1_ Core Function Activities
ResearchCore Leader · Awarded by National Institute for Child Health & Human Develo · 2018 - 2026Application of Physiologically-Based Pharmacokinetic Modeling to Characterize Drug-Drug Interactions in Infants
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2021 - 2026DCRI D-COHRe Partnership for Innovation, Improved Access, and Operational Capability for Decentralized Clinical Trials of Medical Countermeasures in Public Health Emergencies
ResearchCo-Principal Investigator · Awarded by Biomedical Advanced Research and Development Authority · 2024 - 2025Optimal Dosing for Biologic Agents in Obese Patients with Rheumatoid and Juvenile Arthritis
ResearchMentor · Awarded by National Institutes of Health · 2020 - 202518-0006 Mod 6 (EA)
Clinical TrialPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2025Physiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with Obesity
ResearchCo Investigator · Awarded by University of North Carolina - Chapel Hill · 2018 - 2025RADx-UP CDCC
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2025Mentoring in Clinical Pharmacology and Early Phase Trials
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2024Duke CTSA (TL1) Year 5
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024Duke Summer Training in Academic Research (Duke's STAR)
ResearchMentor · Awarded by National Institutes of Health · 2018 - 2024Duration of post-discontinuation antibiotic exposures in premature infants and associated outcomes
ResearchCo-Mentor · Awarded by Thrasher Research Fund · 2021 - 2024ACTIV-1
Clinical TrialCo Investigator · Awarded by Technical Resources International · 2020 - 2023Global Pediatric Clinical Trials Network
ResearchCo-Principal Investigator · Awarded by Food and Drug Administration · 2017 - 2023TASK ORDER FY.2022.A1.01348 - Task Area A
ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2022VTEU HHSN272201300017I/75N93019F00132-FY2020.A1B1C1D1.0123 Task Order #17 16-0076 Task C Option 3 & Task D Option 6 Extension
ResearchInvestigator · Awarded by National Institutes of Health · 2021 - 2022Project 2: Impact of immune-based intervention on viral rebound in orally SHIV infected infant monkeys
ResearchCollaborator · Awarded by Weill Cornell Medicine · 2020 - 2022RTOP 18-0006 Option 1 Mod 5
Clinical TrialPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2022RTOP 18-0006 Option 1 / Protocol Implementation
Clinical TrialPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2022TASK ORDER FY.2021.A1.0128 - Task Area A
ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2020 - 2021Investigating polypharmacy-related adverse events in critically ill children using electronic health records and simulated drug levels
ResearchAdvisor · Awarded by National Institutes of Health · 2017 - 2021VTEU Task D Option 6 - FY.2017.B2C2D2.0053
ResearchInvestigator · Awarded by National Institutes of Health · 2017 - 2021VTEU Task B - FY.2017.B2C2D2.0053
ResearchInvestigator · Awarded by National Institutes of Health · 2016 - 2021VTEU Task D Option 5 - FY.2017.B2C2D2.0053
ResearchInvestigator · Awarded by National Institutes of Health · 2016 - 2021Project 2: The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys
ResearchCollaborator · Awarded by Weill Cornell Medicine · 2020 - 2021UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2020 - 2021PTN 2.0 TO 1 Core Function Activities_Option 2
Clinical TrialCore Leader · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2020 - 2021RTOP 18-0006 Option 1 / Protocol Implementation
Clinical TrialPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2021TASK AREA A, TASK ORDER FY.2020.A1.0127 - Task Area A
ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2020Zika virus pathophysiology during pregnancy
ResearchCollaborator · Awarded by University of Wisconsin - Madison · 2018 - 2020Pharmacokinetics, Pharmacodynamics, and Safety of Methylprednisolone in Neonates on Cardiopulmonary Bypass
ResearchMentor · Awarded by National Institutes of Health · 2017 - 2020Relationship between cerebrospinal fluid penetration of antimicrobials in infants and juvenile animals
ResearchCo Investigator · Awarded by Food and Drug Administration · 2016 - 2020PTN2- TO#4 Data Closeout and Dissemination Option Period I
ResearchPrincipal Investigator · Awarded by National Institute for Child Health & Human Develo · 2019 - 2020P1CTU_Task Order 16_Protocol Implementation (Mod 3)
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2020Admin Supplement: Parmacokinetic and pharmacogenomic approach to indomethacin therapy in pregnancy
ResearchPrincipal Investigator · Awarded by University of Texas Medical Branch · 2018 - 2020P1CTU_Task Order 16_Protocol Implementation
Clinical TrialPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2017 - 2020HCQ Pharmacokinetics in Pediatric Lupus
ResearchMentor · Awarded by Childhood Arthritis & Rheumatology Research Alliance, Inc. · 2019 - 2020Physiologically-Based Pharmacokinetic Models for Optimal Drug Dosing in Children
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2020Pediatric Trials Network_ Task Order 1_ Core Function Activities Option Period 1
ResearchCore Leader · Awarded by National Institute for Child Health & Human Develo · 2019 - 2020VTEU Task Area D Option 9 Protocol FY.2016.D1.0026
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2017 - 2020RTOP 18-0006 Base / Protocol Development
ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2020PTN TO #30 POPS Lab Mod. 2
Clinical TrialPrincipal Investigator · Awarded by National Institute for Child Health & Human Develo · 2017 - 2020POPS Lab
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2020PHASE 1 CLINICAL TRIAL UNITS FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES ADMINISTRATIVE AND OVERALL CLINICAL OPERATIONS SUPPORT AND CONCEPT DEVELOPMENT TASK AREA A TASK ORDER.
ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2018 - 2019PTN2- TO# Data Closeout and Dissemination
ResearchPrincipal Investigator · Awarded by National Institute for Child Health & Human Develo · 2018 - 2019PTN Task Order 25 SCAMP Modification
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2019PTN TO #25 SCAMP
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2013 - 2019P1CTU Protocol Development for 17-0033 (Base)
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2019UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
Inst. Training Prgm or CMEMentor · Awarded by University of North Carolina - Chapel Hill · 2017 - 2019VTEU Task Area D Option 8B Protocol FY.2016.D1.0026
ResearchInvestigator · Awarded by National Institutes of Health · 2016 - 2019Echocardiogram to Diagnose Pulmonary Hypertension in Premature Infants
ResearchCo Investigator · Awarded by University of North Carolina - Chapel Hill · 2015 - 2019PTN Task Order: CAFFEINE
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2014 - 2019TASK AREA A, TASK ORDER FY.2018.A1.0095 Task Area A
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2018VTEU Task Area D Option 8 Protocol FY.2016.D1.0026
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2016 - 2018SOLI - Solithromycin Pediatric Development Program (Phase 2/3)- Labor & Sub Cost
Clinical TrialPrincipal Investigator · Awarded by Cempra Pharmaceuticals, Inc. · 2016 - 2018Hyperimmune globulin treatment of Zika virus during pregnancy to reduce Congenital Zika Syndrome
ResearchCollaborator · Awarded by University of Wisconsin - Madison · 2017 - 2018Duke CTSA (UL1)
ResearchProgram Director · Awarded by National Institutes of Health · 2013 - 2018Pass-Through cost- CLIN04
Clinical TrialPrincipal Investigator · Awarded by Cempra Pharmaceuticals, Inc. · 2016 - 2018Role of pharmacokinetics and genomics in tocolytic therapy with indomethacin (subcontract)
ResearchPrincipal Investigator · Awarded by University of Texas Medical Branch · 2015 - 2018PTN POPS III
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2018P1CTU_Task Order 16_Protocol Development
ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2017 - 2017Phase I CTU Task Area A: Administrative and Overal Clinical Operations Support and Concept Development, Year 3
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2017PTN Task Order #17: Bioanalytical Analysis: POPS1, Fluconazole, and Meropenem
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2017SOLI - Solithromycin Pediatric Development Program (Phase 2/3 start up)- MOD 2
Clinical TrialPrincipal Investigator · Awarded by Cempra Pharmaceuticals, Inc. · 2016 - 2017TASK AREA A TASK ORDER FY.2016.A1.0041
ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2015 - 2016SOLI - Solithromycin Pediatric Development Program (Phase IB)- MOD 2
Clinical TrialPrincipal Investigator · Awarded by Cempra Pharmaceuticals, Inc. · 2014 - 2016Clinical Practice Data to Aid Narrow Therapeutic Index Drug Classification
ResearchPrincipal Investigator · Awarded by Food and Drug Administration · 2013 - 2016PTN Task Order #19: Lorazepam
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2012 - 2016PTN Task Order 29: Clindamycin Bactrim
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2016CISA TO2 Prophylactic Antipyretics Revision 3-A
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2014 - 2016CISA TO2 Prophylactic Antipyretics Revision 1-A
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2014 - 2016CISA TO2 Prophylactic Antipyretics
ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2013 - 2016PTN Task Order #20: POPS II
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2016DAP Phase I PK/PD Analysis Budget
ResearchCo-Principal Investigator · Awarded by Jacobus Pharmaceutical Company, Inc. · 2016 - 2016The Pharmacokinetics of Extended Duration High-dose Cefixime Co-administered with Azithromycin for the Decreased Susceptibility of Neisseria gonorrhoeae: A Phase I Pilot Study, Option 1
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2016The Pharmacokinetics of Extended Duration High-dose Cefixime Co-administered with Azithromycin for the Decreased Susceptibility of Neisseria gonorrhoeae: A Phase I Pilot Study
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2016Role of pharmacokinetics and genomics in tocolytic therapy with indomethacin (subcontract)
ResearchPrincipal Investigator · Awarded by University of Texas Medical Branch · 2015 - 2016Phase I CTU Task Area A: Administrative and Overal Clinical Operations Support and Concept Development
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2015Pharmacokinetics and Pharmacodynamics of Antibiotics in Premature Infants
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2010 - 2015VTEU 13-0053 Task Area B: Phase I, single dose, open-label, parallel group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, normal, healthy subjects.
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2014 - 2015PTN Task Order #3 - Safety and Pharmacokinetics of Multiple Dose Metronidazole in Premature Infants
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2010 - 2013CTSA UL
ResearchJunior Faculty · Awarded by National Institutes of Health · 2006 - 2012Best Pharmaceutical for Children Act (BPCA): Use of Meropenem in Infants
Clinical TrialFellow · Awarded by National Institutes of Health · 2007 - 2010External Relationships
- ExecRx
- GlaxoSmithKline
- Leo Pharmaceuticals
- Lightship
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.